NAPLES, Fla., Feb. 9, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer…
Read More
Advancing pipeline with naturally occurring and synthetic compounds initially focused on the development of cannabinoids for pharmaceutical use Enveric has assembled a highly accomplished executive team, Board of Directors and…
NAPLES, Fla., Jan. 15, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer…
NAPLES, Fla., Jan. 12, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that…
Industry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape NAPLES, Fla., Jan. 5, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology…
